Venture Life Group PLC Director/PDMR Shareholding (5183V)

TIDMVLG

RNS Number : 5183V

Venture Life Group PLC

05 April 2023

5April 2023

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Director Dealings

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that Mark Adams, Non-Executive Director, today purchased 58,504 ordinary shares of 0.3p each in the Company ("Ordinary Shares") at a volume weighted average price of 42.73 pence per Ordinary Share.

Following this purchase, Mr Adams beneficially holds 58,504 Ordinary Shares representing approximately 0.05 per cent. of the Company's issued share capital.

For further information, please contact:

 
                                                     +44 (0) 1344 
 Venture Life Group PLC                               578004 
 Jerry Randall, Chief Executive Officer 
  Daniel Wells, Chief Financial Officer 
 
                                                       [phone] 
   Cenkos Securities plc (Nomad and Broker)            8900 
 Stephen Keys / Camilla Hume 
 Russell Kerr / Michael Johnson (Sales) 
 
   Singer Capital Markets (Joint Broker) 
   Shaun Dobson / Alaina Wong (Corporate Finance)      [phone] 
   Jonathan Dighe (Sales)                              3000 
 

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands, these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies for consumer healthcare products, primarily medical devices.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

 
      Details of the person discharging managerial responsibilities 
  1    / person closely associated 
 a)   Name                        Mark Adams 
     --------------------------  ---------------------------------------- 
      Reason for the notification 
  2 
     -------------------------------------------------------------------- 
 a)   Position/status             Non-Executive Director 
     --------------------------  ---------------------------------------- 
 b)   Initial notification        Initial notification 
       /Amendment 
     --------------------------  ---------------------------------------- 
      Details of the issuer, emission allowance market participant, 
  3    auction platform, auctioneer or auction monitor 
     -------------------------------------------------------------------- 
 a)   Name                        Venture Life Group plc 
     --------------------------  ---------------------------------------- 
 b)   LEI                         213800S8CZUPLAB2KC70 
     --------------------------  ---------------------------------------- 
      Details of the transaction(s): section to be repeated 
  4    for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     -------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of 0.3p each in Venture 
       financial instrument,       Life Group plc 
       type of instrument 
 
 
       Identification code         GB00BFPM8908 
     --------------------------  ---------------------------------------- 
 b)   Nature of the transaction   Purchase of ordinary shares 
     --------------------------  ---------------------------------------- 
 c)   Price(s) and volume(s)       Price    Volume 
                                    42.74p   23,397 
                                            ------- 
                                    42.71p   23,412 
                                            ------- 
                                    42.75p   11,695 
                                            ------- 
     --------------------------  ---------------------------------------- 
 d)   Aggregated information      See above 
 
 
       - Aggregated volume 
 
 
       - Price 
     --------------------------  ---------------------------------------- 
 e)   Date of the transaction     5 April 2023 
     --------------------------  ---------------------------------------- 
 f)   Place of the transaction    London Stock Exchange 
     --------------------------  ---------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFEFSIIEIIV

(END) Dow Jones Newswires

April 05, 2023 08:53 ET (12:53 GMT)